在治疗耐药抑郁症中的抑郁症状集群上,rTMS和抗抑郁药物之间的比较
Iris Dalhuisen1, Tom Biemans2,3, Cornelis F Vos2,4
1Department of Psychiatry, Radboud University Medical Center, Nijmegen, The Netherlands. iris.dalhuisen@radboudumc.nl.
European archives of psychiatry and clinical neuroscience
|April 23, 2025
概括
重复性跨磁刺激 (rTMS) 和抗抑郁药物治疗对抑郁症症状集群的有效性相似. 失眠症状对治疗反应最好,但基线得分不能预测结果.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 临床心理学 临床心理学
背景情况:
- 抑郁症治疗结果通常通过总分数来评估,但症状集群可能会提供更细致的观点.
- 不同治疗方法对特定抑郁症症状集群的比较有效性尚不清楚.
- 这项研究评估了rTMS和抗抑郁药物对四个不同的症状集群的影响.
研究的目的:
- 为了比较rTMS和抗抑郁药物在"一般抑郁症"",焦虑症"",身体症状"和"失眠"集群中的有效性.
- 为了确定基线症状集群得分是否预测治疗反应.
- 用两项独立临床试验的数据验证发现.
主要方法:
- 利用了DETECT (rTMS与药物对比) 和PITA (三环抗抑郁药) 试验的数据.
- 采用共变量的多变量分析 (MANCOVA) 来比较rTMS和药物对症状集群的影响.
- 在响应者和非响应者之间以及治疗组之间比较了基线症状集群得分.
主要成果:
- 在rTMS和抗抑郁药物之间,在它们对分析的症状集群的影响方面没有发现显著差异.
- 所有治疗组在集群中都显示出类似的反应模式,其中"失眠"显示出最显著的治疗效果.
- 基线症状集群评分无法预测患者对任何一种治疗方式的反应.
结论:
- 在这项研究中,rTMS和抗抑郁药物都没有显示出对抑郁症状集群的差异效应.
- 这两种治疗方式在所有症状集群中都表现出可比的反应模式.
- 基线症状集群评分没有区分治疗响应者和不响应者,这表明需要进一步研究更大,更均的样本以实现个性化治疗策略.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
160
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
160
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
227
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
227
Electroconvulsive Therapy
18
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
18


